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Selective laser trabeculoplasty versus eye drops for first-line 
treatment of ocular hypertension and glaucoma (LiGHT): 
a multicentre randomised controlled trial
Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, Anurag Garg, Victoria Vickerstaff, Rachael Hunter, Gareth Ambler, Catey Bunce, 
Richard Wormald, Neil Nathwani, Keith Barton, Gary Rubin, Marta Buszewicz; on behalf of the LiGHT Trial Study Group*
Summary
Background Primary open angle glaucoma and ocular hypertension are habitually treated with eye drops that lower 
intraocular pressure. Selective laser trabeculoplasty is a safe alternative but is rarely used as first-line treatment. We 
compared the two.
Methods In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma 
or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. 
They were randomly allocated (web-based randomisation) to initial selective laser trabeculoplasty or to eye drops. 
An objective target intraocular pressure was set according to glaucoma severity. The primary outcome was health-
related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, 
disease-specific HRQoL, clinical effectiveness, and safety. Analysis was by intention to treat. This study is registered 
at controlled-trials.com (ISRCTN32038223).
Findings Of 718 patients enrolled, 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops 
group. 652 (91%) returned the primary outcome questionnaire at 36 months. Average EQ-5D score was 0·89 (SD 0·18) 
in the selective laser trabeculoplasty group versus 0·90 (SD 0·16) in the eye drops group, with no significant difference 
(difference 0·01, 95% CI –0·01 to 0·03; p=0·23). At 36 months, 74·2% (95% CI 69∙3–78∙6) of patients in the selective 
laser trabeculoplasty group required no drops to maintain intraocular pressure at target. Eyes of patients in the 
selective laser trabeculoplasty group were within target intracoluar pressure at more visits (93·0%) than in the eye 
drops group (91·3%), with glaucoma surgery to lower intraocular pressure required in none versus 11 patients. Over 
36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as 
first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted 
life-year gained.
Interpretation Selective laser trabeculoplasty should be offered as a first-line treatment for open angle glaucoma and 
ocular hypertension, supporting a change in clinical practice.
Funding National Institute for Health Research, Health and Technology Assessment Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Glaucoma is a progressive multifactorial disease 
characterised by damage to the optic nerve and 
progressive visual loss that, if left untreated, can lead to 
blindness. It is a significant cause of visual morbidity, 
accounting for falls,1 road traffic accidents, loss of 
independence,2 and 12% of blind registrations.3 Open 
angle glaucoma (OAG) is the most common form, with 
a prevalence of about 2% among adults older than 
40 years;4 it is strongly associated with elevated intra­
ocular pressure. Lowering intraocular pressure can 
slow progression of the disease and is the only treat­
ment available.5 Raised intraocular pressure without 
optic nerve damage is termed ocular hypertension, 
which, in some patients, progresses to open angle 
glaucoma; lowering intraocular pressure reduces 
this risk.6
The standard first­line treatment for OAG and ocular 
hypertension is eye drops that lower intraocular 
pressure, requiring multiple hospital visits for moni­
toring and treatment adjustment. Long­term and mul­
tiple topical medications are associated with multiple 
ocular and systemic side­effects, poor patient adherence, 
and are a risk factor for later surgical failure.7,8 Selective 
laser trabeculo plasty reduces intra ocular pressure by 
inc reasing aqueous outflow through the trabecular 
meshwork with a single, painless out patient laser 
procedure, minimal recovery time, and good safety 
profile. It was introduced in 1995 and received US FDA 
approval in 2001, yet is not routinely offered as first­line 
treatment. Selective laser trabeculoplasty superseded 
argon laser trabeculoplasty, with fewer ad verse events, 
greater ease of use, and improved repeat ability.9 The 
intraocular pressure­lowering effect is compar able to 
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medical treatment and can delay or pre vent the need for 
eye drops, avoiding the associated side­effects. The effect 
of selective laser trabeculoplasty is not permanent, but it 
can be repeated. When successful, it reduces the risk of 
non­adherence, by removing or lessening the need for 
complex treatment regimes.
Glaucoma has an adverse effect on health­related quality 
of life, through progressive loss of field of vision and the 
inconvenience and side effects of treatments including eye 
drops and surgery.10,11 The treatment of OAG and ocular 
hypertension also imposes significant financial costs. The 
cost benefits of selective laser trabeculoplasty have been 
modelled for a variety of health­care systems,12 but direct 
evidence on its cost­effectiveness as a primary treatment is 
lacking.
We carried out a multicentre randomised controlled trial 
to compare eye drops versus selective laser trabeculoplasty 
as first­line treatment for OAG or ocular hypertension. We 
also compared the clinical effectiveness and cost­
effectiveness of the two approaches. We hypothesised that 
selective laser trabeculoplasty as a first­line treatment 
would be associ ated with better health­related quality of 
life, less need for topical medication, and lower cost.
Methods
Study design and participants
Details of the trial design and baseline characteristics 
of the Laser in Glaucoma and ocular HyperTension 
(LiGHT) study are described elsewhere.13,14 Consecutive, 
newly referred patients were identified at six hospitals 
across the UK (appendix p 1) between Oct 10, 2012, and 
Oct 27, 2014. Eligible patients had newly diagnosed, 
untreated OAG or ocular hyper tension in one or both 
eyes, qualified for treatment according to NICE 
guidelines,15 and, for those with OAG, had visual field 
loss with mean deviation not worse than –12 dB in the 
better eye or –15 dB in the worse eye and corresponding 
damage to the optic nerve. Patients were aged 18 years or 
older, able to read and understand English, had a visual 
acuity of 6/36 or better in the eyes to be treated, and no 
previous intraocular surgery, except uncomplicated 
phacoemulsification at least 1 year before randomisation. 
Patients were excluded if there were contraindications to 
selective laser trabeculoplasty (eg, unable to sit at the slit­
lamp mounted laser, past history of uveitis, inadequate 
view of trabecular mesh work), if they were unable to use 
eye drops, had symptomatic cataract, or were under 
active treatment for another ophthalmic condition. 
Patients were monitored for 36 months.
We wished to capture the complexities of normal 
clinical practice, including any effects that knowledge of 
treatment might have on patient behaviour, and yet to 
avoid potential bias arising from clinical decision making 
when patients and clinicians were not masked to 
treatment allocation. To achieve this, we used disease 
severity and pre­treatment intraocular pressure to set 
Research in context
Evidence before this study
A Cochrane systematic review published in 2007, highlighted 
the need for research comparing the clinical efficacy and 
cost-effectiveness of selective laser trabeculoplasty to eye 
drops, for lowering intraocular pressure for the treatment of 
open angle glaucoma or ocular hypertension. We did a literature 
search in June, 2018. We used the MEDLINE through PubMed 
using the search terms “selective laser trabeculoplasty”; “SLT”; 
“laser trabeculoplasty”; and “original research studies”.
Two meta-analyses were published in 2015, showing that 
360-degree selective laser trabeculoplasty gives a similar 
reduction in intraocular pressure to either prostaglandin 
analogue monotherapy or combination therapy. The studies 
reviewed had adopted various follow-up periods and a wide 
range of success criteria. In terms of cost-effectiveness, 
selective laser trabeculoplasty has been modelled to be 
cost-effective when compared to medical lowering of 
intraocular pressure, but no studies used direct measurements 
of costs. Since the publication of the Cochrane systematic 
review, the time threshold at which selective laser 
trabeculoplasty becomes cost-effective against intraocular 
pressure-lowering drops has been modelled and estimated to 
be 1–3∙3 years, depending on the cost of drops. Selective laser 
trabeculoplasty has also been predicted to be cost-effective 
when repeated once within 3 years of initial application 
compared to monotherapy or multiple drug therapy. 
The economic data available have been based on the Canadian, 
US, or Australian health-care systems.
Added value of this study
This trial shows that selective laser trabeculoplasty is safe and 
effective as a first-line treatment for open angle glaucoma and 
ocular hypertension. Selective laser trabeculoplasty provides 
superior intraocular pressure stability to drops, at a lower cost 
and, importantly, it allows almost three quarters of 
patients (74%) to be successfully controlled without drops for at 
least 3 years after starting treatment. This is the first trial of a 
direct comparison between selective laser trabeculoplasty and 
intraocular pressure-lowering drops in terms of health-related 
quality of life, clinical, and cost-effectiveness outcomes in a 
pragmatic hospital setting, guided by a robust treatment 
escalation protocol to capture realistic clinical management while 
minimising risk of bias. It also suggests that measurements of 
generic health-related quality of life have limited discriminatory 
power in demonstrating treatment effects in glaucoma.
Implications of all the available evidence
Selective laser trabeculoplasty is associated with lower cost, 
good clinical outcomes, with lower symptom scores, 
and drop-freedom for most patients and should be offered as 
an alternative to intraocular pressure-lowering drops.
See Online for appendix
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objective patient­specific intraocular pressure targets, 
treatment intensities, and monitoring intervals (adjusted 
on the basis of intraocular pressure control, disease 
stability, or adverse reactions). This approach was guided 
by a defined protocol, using decision support software 
based on published criteria. Deviations from decision 
support­recommended interventions were recorded.14
The study was conducted in accordance with good 
clinical practice guidelines and adhered to the tenets of 
the Declaration of Helsinki. Ethical approval was granted 
by local boards of each participating centre. All patients 
provided written informed consent before participation. 
An independent data and safety monitoring committee 
was appointed by the independent trial steering 
committee, to whom adverse events were reported 
according to standard operating procedures. The protocol 
is available online.
Randomisation and masking
We randomised participants using a web­based system 
(www.sealedenvelope.com) We randomly assigned 
patients (1:1) to either eye drops or selective laser 
trabeculoplasty as first­line treatment. We used stratified 
randomisation, with diagnosis (ocular hypertension vs 
OAG) and treat ment centre as stratification factors, with 
random block sizes (of four, six, or eight). All 
measurements influencing treatment escalation decisions 
(visual field, optic disc imaging, and intraocular pressure) 
were made by observers masked to treatment allocation. 
Clinicians and patients were not masked to treatment 
allocation.
Procedures
Patients with one or both eyes eligible were treated 
identically. Participants were treated along two treatment 
pathways depending on their random allocation: either 
topical medication to lower intraocular pressure (the eye 
drops group) or primary selective laser trabeculoplasty 
followed by topical medications as required (the selective 
laser trabeculoplasty group). We used NICE thresholds15 
for disease definition (OAG or ocular hypertension) and 
treatment initi ation, incorporated into real­time web­based 
clinical decision support software, which was based on 
optic disc analysis using Heidelberg retina tomography 
(Heidelberg Engineering, Heidelberg, Germany), auto­
mated visual field assessment using the Humphrey 
Field Analyzer Mark II Swedish interactive threshold 
algorithm standard 24­2 programme (Carl Zeiss Meditec, 
Dublin, CA, USA), and intraocular pressure measurements 
(Goldmann applanation tonometry with daily calibration). 
Disease category and stage were defined at baseline, using 
preset objective severity criteria from the Canadian Target 
IOP Workshop16 with additional central visual field loss cri­
teria according to Mills and colleagues.17
Eye­specific target intraocular pressure and patient 
follow­up intervals were based on the Canadian Target 
IOP Workshop16 for disease severity stratification (mild, 
moderate, or severe), with the target intraocular pressure 
determined from both a percentage reduction (20% or 
30% depending on the patient’s clinical characteristics) 
from a single untreated baseline measure ment and 
an absolute threshold. Deterioration of glaucoma (ie, 
progression) and conversion of ocular hyper tension to 
OAG was derived from the decision support software 
(based on visual field and Heidelberg retina tomography 
data) and verified by a consultant ophthalmologist. 
Objective visual field and optic nerve head imaging 
criteria using the incorporated Humphrey Glaucoma 
Progression Analysis software, as used by the Early 
Manifest Glaucoma Trial,18 requiring four consecutive 
visual field tests, and Heidelberg retina tomography rim 
area, respectively, defined strong evidence and less strong 
evidence of deterioration. Strong evidence was defined as 
“likely progression” according to Glaucoma Progression 
Analysis or Heidelberg retina tomography rim area 
greater than 1% per year (p <0∙001); less strong evidence 
was defined as “possible progression” on Glaucoma 
Progression Analysis or Heidelberg retina tomography 
rim area greater than 1% per year (p<0∙01).14
Treatment escalation followed international guidelines 
of the European Glaucoma Society,19 American Academy 
of Ophthalmology Preferred Practice Pattern,20 and 
South­East Asia Glaucoma Interest Group.21 Treatment 
was escalated when there was either: (1) strong evidence 
of deterioration irrespective of intra ocular pressure, 
(2) intraocular pressure above the target by more than 
4 mm Hg at a single visit, or (3) intraocular pressure 
above the target by less than 4 mm Hg and less strong 
evidence of progression. Target intraocular pres sure was 
reduced by 20% if deterioration was identified despite 
the measured intraocular pressure being at or below 
target. If the intraocular pressure was above target by less 
than 4 mm Hg, but with no evidence of de terioration, 
then the target intraocular pressure was revised to the 
mean of the previous three visits over which deterioration 
had not occurred.
Standardisation of laser delivery was achieved by 
protocol­defined settings and clinical endpoints.14 Selec­
tive laser trabeculoplasty was delivered to 360° of 
the trabecular meshwork. 100 non­overlapping shots 
(25 per quadrant) were used, with the laser energy varied 
from 0∙3 to 1∙4 mJ by the clinician, using an appropriate 
laser gonioscopy lens. One re­treatment with selective 
laser trabeculoplasty was allowed, pro vided there had 
been a reduction in intraocular pressure after the initial 
treatment; the next escalation was medical therapy. 
Significant complications of selective laser trabeculoplasty 
(eg, a spike in intraocular pressure) precluded repetition 
of selective laser trabeculoplasty.
Drug classes for first, second, or third line treatment 
were defined by NICE15 and European Glaucoma 
Society19 guidance (first line was prostaglandin 
analogues, second line was β blockers, third or fourth 
line was topical carbonic anhydrase inhibitors or 




4 www.thelancet.com   Published online March 9, 2019   http://dx.doi.org/10.1016/S0140-6736(18)32213-X
α agonists). Fixed combin ation drops were allowed. 
Systemic carbonic anhydrase inhibitors were only 
permitted while awaiting surgery. Maximum tolerated 
medical therapy was defined by the treating clinician as 
the most intensive combi nation of drops an individual 
could reasonably, reliably, and safely use and thus varied 
between patients. A need for treatment escalation 
beyond maximum tolerated medical therapy triggered 
an offer of surgery.
An adverse event was defined as an unfavourable 
medical occurrence in a patient, not necessarily caused 
by treatment. Adverse events were classified as serious 
according to good clinical practice guidelines.22 Adverse 
events were reported according to standard operating 
procedures and good clinical practice guidelines, and 
reported annually to the research and ethics committee 
and the trial sponsor.
Outcomes
The primary outcome measure was health­related quality 
of life measured using the EuroQol EQ­5D 5 Levels 
(EQ­5D­5L) utility scores at 36 months. Utility scores were 
calculated from patient reported health states using the 
EQ­5D descriptive system and value set for England.23 The 
secondary outcomes were: glaucoma­specific treatment­
related quality of life assessed with the Glaucoma Utility 
Figure 1: Trial profile
SLT=selective laser trabeculoplasty. *Two patients were randomised twice due to computer failure: one was initially 
randomised to medication but was subsequently randomised to, and received, SLT. The other was initially 
randomised to SLT but was subsequently randomised to, and received, medication. These patients are included in 
the figure according to their second randomisations. In addition, four other patients who did not meet the 
eligibility criteria (and could not receive treatment) were randomised in error. These patients were subsequently 
removed from the study and are not included in the total randomised.
356 allocated to SLT
355 received allocated intervention 
1 withdrew consent before 
treatment 
16 discontinued 
1 was longer contactable
1 moved to another hospital
3 withdrew from the trial
8 died
3 ill health and unfit to continue
9 discontinued 
1 no longer contactable
3 moved to another hospital
1 withdrew from the trial
2 died 
2 ill health and unfit to continue
362 allocated to eye drops
361 received allocated intervention
1 decided to receive SLT after 
randomisation 
329 analysed 
11 did not return the primary 
outcome at 36 months
323 analysed
30 did not return the primary 
outcome at 36 months
16 379 patients assessed for eligibility 
15 661 excluded 
15 483 did not meet inclusion criteria
178 declined to participate
43 did not want to have SLT
17 did not want to take part in research
9 did not want to use drops
3 did not want any treatment
1 did not want to travel to the hospital







Moorfields Eye Hospital 187 (51∙7%) 187 (52∙5%)
Huntingdon Hospital 41 (11∙3%) 41 (11∙5%)
Guy’s and St Thomas’ Hospital 55 (15∙2%) 51 (14∙3%)
Queen’s University Belfast 15 (4∙1%) 15 (4∙2%)
Norfolk and Norwich University 
Hospital
46 (12∙7%) 43 (12∙1%)
York Hospital 18 (5.0%) 19 (5∙3%)
Mean age (years, SD) 62∙7 (11∙6%) 63∙4 (12∙0%)
Sex
Male 197 (54∙4%) 200 (56∙2%)
Female 165 (45∙6%) 156 (43∙8%)
Ethnicity*
Asian 28 (7∙7%) 23 (6∙5%)
Black 69 (19∙1%) 77 (21∙6%)
White 258 (71∙3%) 243 (68∙3%)
Other 7 (1∙9%) 13 (3∙7%)
Diagnosis
OAG 282 (77∙9%) 273 (76∙7%)
OHT 80 (22∙1%) 83 (23∙3%)
Other health conditions
Asthma 45 (12∙4%) 48 (13∙5%)
Hypertension 119 (32∙9%) 132 (37∙1%)
Diabetes 40 (11∙1%) 42 (11∙8%)
Angina 11 (3∙0%) 10 (2∙8%)
Cardiac arrhythmia 20 (5∙5%) 17 (4∙8%)
Medication
Statins 92 (25∙4%) 104 (29∙2%)
Systemic β blockers 12 (3∙3%) 22 (6∙2%)
Calcium channel blocker 60 (16∙6%) 56 (15∙7%)
ACE inhibitors 43 (11∙9%) 57 (16∙0%)
Corticosteroids 20 (5∙5%) 22 (6∙2%)
Family history of glaucoma† 107 (29∙6%) 107 (30∙1%)
Highest education achieved
Degree or equivalent (≥16 years of 
education completed)
106 (29∙3%) 110 (30∙9%)
Higher education (≥15 years) 39 (10∙8%) 55 (15∙5%)
A-level or equivalent (13 years) 49 (13∙5%) 39 (11.0%)
GCSEs (11 years) 84 (23∙2%) 71 (19∙9%)
Other qualifications (≥11 years) 30 (8∙3%) 29 (8∙2%)
No qualifications (11 years) 54 (14∙9%) 52 (14∙6%)
SLT=selective laser trabeculoplasty. OAG=primary open angle glaucoma. OHT=ocular 
hypertension. ACE=angiotensin-converting enzyme inhibitor.*Self-defined ethnicity 
as per National Health Service categories: Asian ethnicity refers to Indian, Pakistani, 
Bangladeshi, and any other south Asian background; black ethnicity refers to 
Caribbean, African, and any other black background; other ethnicity refers to Chinese 
and any other ethnic group. †In a first degree relative. 
Table 1: Baseline patient characteristics
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Index (GUI),24 patient­reported disease and treatment­
related symptoms assessed using the Glaucoma Symptom 
Scale (GSS);25 patient­reported visual function assessed 
using the Glaucoma Quality of Life­15 questionnaire 
(GQL­15); health­care resource use, collected from patients’ 
files and from a modified version of the Client Service 
Receipt Inventory (appendix pp 11–15), clinical effective­
ness (proportion of visits at target intraocular pressure, 
number of treatment escalations), visual func tion (visual 
acuity, visual fields), and safety. The EQ­5D, GUI, GSS, 
GQL­15, and Client Service Receipt Inventory were 
completed at 6­monthly intervals by postal question naire, 
backed up by telephone or online follow­up.
Statistical analysis
The statistical analysis plan has been described in detail 
previously.26 We calculated that a sample size of 718 patients 
was needed to detect a difference of 0∙05 in EQ­5D 
between the two groups using a two sample t test at 
the 5% significance level with 90% power, assuming a 
common standard deviation of 0∙19 and 15% attrition.
The primary outcome was analysed using linear 
regression with terms for randomisation group, base line 
EQ­5D, stratification factors (diagnosis and centre), 
baseline intraocular pressure, and number of eyes 
affected at baseline. The unit of analysis was the patient. 
If a patient had both eyes in the study, baseline severity 
and intraocular pressure were based on the worse eye, 
where the worst eye was defined using visual field loss 
with mean deviation at baseline. Missing values of 
EQ­5D at 36 months were imputed using values from 
30 months, when available. Several sensitiv ity analyses 
were performed to verify the results of the primary 
analysis (appendix p 25). In addition, mixed effects 
models were used to analyse the EQ­5D measurements 
recorded at all timepoints to investigate possible changes 
in treat ment effect over the 36 months (using interaction 
terms between random isation group and time) and to 
estimate the average treatment effect over the 36­month 
follow­up period.
The secondary outcomes were analysed using similar 
regression methods to those described above. All anal­
yses were performed on an intention­to­treat basis with 
participants analysed according to the group to which 
they were allocated. All analyses were performed in Stata 
(version 14).
For our economic assessment, we calculated quality­
adjusted life­years (QALYs) from utility scores over the 
36­month period using the baseline and 6­monthly 
follow­up EQ­5D questionnaires and calculating the area 
under the curve. Health­care resource use was based on 
cost using published sources (appendix pp 23–24). The 
cost of drops for OAG and ocular hypertension based on 
prescribed medications, using the British National 
Formulary.27 We report cost­effectiveness acceptability 
curves and the probability that the inter vention is cost­
effective for a range of values of willingness to pay. Full 
details of the methodology for the economic evaluation 
can be found in the appendix (pp 19–25).
This study is registered at controlled­trials.com 
(ISRCTN32038223).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
718 patients (1235 eyes) were randomly assigned: 
356 patients (613 eyes) to SLT and 362 patients (622 eyes) 
to eye drops (figure 1). One patient (two eyes) allocated to 
selective laser trabeculoplasty withdrew consent before 
treat ment. Two patients were assigned twice because of a 
computer error, where the initial randomisation was not 
Number of eyes with 
data (patients)
Eye drops (n=622 eyes; 
362 patients)
SLT (n=613 eyes; 
356 patients)
Diagnosis 1235 (718) ∙∙ ∙∙
Ocular hypertension ∙∙ 185 (29∙7%) 195 (31∙8%)
Mild OAG ∙∙ 325 (52∙3%) 311 (50∙7%)
Moderate OAG ∙∙ 77 (12∙4%) 67 (10∙9%)
Severe OAG ∙∙ 35 (5∙6%) 40 (6∙5%)
Refractive error (spherical D) 1225 (713) –0∙2 (2∙7) –0∙3 (3∙2)
Visual acuity 1235 (718) 0∙1 (0∙1) 0∙1 (0∙2)
Visual field mean deviation (dB) 1233 (717) –3∙0 (3∙6) –3∙0 (3∙4)
HRT rim area (mm2) 1128 (656) 1∙1 (0∙4) 1∙2 (0∙4)
Intraocular pressure (mm Hg) 1233 (717) 24∙4 (5∙0) 24∙5 (5∙2)
CCT (µm) 1229 (715) 551∙6 (36∙2) 550∙7 (38∙1)
Pseudo-exfoliation 1233 (717) 12 (1∙9%) 5 (0∙8%)
Pseudophakia 1233 (717) 33 (5∙3%) 39 (6∙4%)
Data are n (%) or mean (SD). SLT=selective laser trabeculoplasty. OAG=primary open angle glaucoma. HRT=Heidelberg 
retina tomograph. CCT=central corneal thickness. 
Table 2: Baseline ocular characteristics
Eye drops (n=362) SLT (n=355)
EQ-5D* 0∙92 (0∙13) 0∙91 (0∙13)
Glaucoma Utility Index*† 0∙89 (0∙11) 0∙89 (0∙12)
Glaucoma Symptom Scale†‡ 83∙3 (16∙6) 81∙4 (17∙2)
Symptom subscale 81∙2 (19∙4) 79∙1 (20∙1)
Function subscale 86∙4 (17∙3) 84∙8 (17∙8)
Glaucoma Quality of Life-15§ 18∙7 (5∙6) 18∙9 (6∙6)
Central subscale 2∙5 (1.0) 2∙5 (1.0)
Peripheral subscale 8∙4 (2∙9) 8∙5 (3∙4)
Dark subscale 7∙9 (2∙8) 7∙9 (3.0)
Outdoor subscale 1∙1 (0∙4) 1∙1 (0∙4)
Data are mean (SD). SLT=selective laser trabeculoplasty. EQ-5D=EuroQol EQ-5D. 
*n=716. †Higher scores indicate better health-related quality of life. ‡n=710. 
§Higher scores indicate worse health-related quality of life.
Table 3: Baseline questionnaire scores
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visible. Subsequently, a second randomisation for these 
patients was carried out; one patient was initially random­
ised to eye drops but was subsequently randomised to, and 
received, selective laser trabeculoplasty. The second patient 
was initially randomised to selective laser trabeculoplasty 
but was later randomised to, and received, eye drops. Four 
patients who did not meet the eligibility criteria were 
randomised in error and were subsequently removed 
from the study. Data for the primary outcome were 
available for 652 (91%) of 718 patients at 36 months 
(329 [92%] of 356 in the selective laser trabeculoplasty 
group and 323 [89%] of 362 in the eye drops group) and 
were included in the intention­to­treat analysis (with 
imputation used for missingness; figure 1). There were 
30 protocol violations or deviations without an effect on 
safety or clinical outcomes (four non­eligible patients were 
randomised, one received eye drops despite randomi­
sation to selective laser trabeculoplasty, and one had a 
third selective laser trabeculoplasty at the consultant’s 
discretion; there were  17 incorrect appoint ment intervals, 
five incorrect visual field software versions, one Heidelberg 
retina tomography was not done, and the decision support 
software was inappropriately run once).
Baseline patient and eye characteristics were similar 
in the treatment groups (tables 1 and 2); 555 patients 
had OAG (in at least one eye) and 163 had ocular 
hypertension. In 517 (72·0%) of 718 patients both eyes 
were eligible, in 96 patients (13·4%) only the right was 
eligible, and in 105 patients (14·6%) only the left. The 
two treatment groups had similar average EQ­5D, GUI, 
and GQL­15 scores at baseline (table 3). The eye drops 
group had slightly higher average GSS scores at 
baseline compared to the selective laser trabeculoplasty 
group (table 3).
At 36 months, the eye drops group had an average 
EQ­5D score of 0·90 (SD 0·16), compared with 0·89 
(SD 0·18) in the selective laser trabeculoplasty group, 
with no significant difference between the two treat­
ments (adjusted mean difference [selective laser 
trabeculoplasty–eye drops] 0·01, 95% CI –0·01 to 0·03, 
p=0·23; table 4, figure 2); the results were confirmed in 
sensitivity analyses (data not shown).
Taking into account the outcome data from all time­
points across 36 months, the two treatment arms had 
similar EQ­5D scores at 36 months (adjusted mean 
difference 0·02, 95% CI –0·00 to 0·03); and when 
using exact times of questionnaire returns (0·01, 
–0·01 to 0·02). The average GUI score at 36 months in 
the selective laser trabeculoplasty group was 0·89 
(SD 0·13) compared with 0·89 (SD 0·13) for the eye 
drops group (adjusted mean difference 0·01, 95% CI 
–0·01 to 0·03). Mean GQL­15 scores were also similar 
between the two groups (19·8 for selective laser 
trabeculoplasty and 19∙8 eye drops, adjusted mean 
difference –0·4, 95% CI –0·6 to 1·3). For the GSS the 
selective laser trabeculoplasty group had a mean score 
of 83·3 (SD 17·3) at 36 months, compared with 83·1 
(SD 17·7) for the eye drops group (adjusted mean 
difference 1·6, 95% CI –0·8 to 4·0). Repeated measures 
analysis showed worse GSS scores for the eye drops 
group at five out of six timepoints over 36 months 
(table 4, figure 2). Secondary outcomes (GUI, GSS, 
Eye drops SLT Adjusted mean 
difference* (95% CI)
p value
n Mean (SD) n Mean (SD)
Analysis at 36 months
EQ-5D 336 0∙89 (0.18) 337 0∙90 (0.16) 0∙01 (–0∙01 to 0∙03) 0∙230
GUI 299 0∙89 (0∙13) 303 0∙89 (0∙13) 0∙01 (–0∙01 to 0∙03) ∙∙
GSS 281 83∙3 (17∙3) 294 83∙1 (17∙7) 1∙6 (–0∙8 to 4∙0) ∙∙
GQL-15 297 19∙8 (7∙8) 304 19∙8 (7∙2) –0∙4 (–1∙3 to 0∙6) ∙∙
QALY 263 2∙70 (0∙42) 261 2∙74 (0∙37) 0∙025 (–0∙02 to 0∙07) 0∙289
QALY (discounted) 263 2∙62 (0∙41) 261 2∙65 (0∙36) 0∙024 (–0∙02 to 0∙07) 0∙286
Repeated measures analysis
EQ-5D
Baseline 362 0∙92 (0∙13) 355 0∙91 (0∙13) ∙∙ ∙∙
6 months 332 0∙90 (0∙15) 330 0∙91 (0∙13) 0∙01 (–0∙01 to 0∙03) ∙∙
12 months 327 0∙91 (0∙14) 327 0∙91 (0∙14) 0∙01 (–0∙01 to 0∙02) ∙∙
18 months 329 0∙90 (0∙16) 325 0∙90 (0∙16) 0∙00 (–0∙02 to 0∙02) ∙∙
24 months 326 0∙91 (0∙14) 326 0∙91 (0∙14) 0∙00 (–0∙02 to 0∙02) ∙∙
30 months 320 0∙90 (0∙15) 317 0∙90 (0∙15) 0∙00 (–0∙01 to 0∙02) ∙∙
36 months 323 0∙89 (0∙18) 329 0∙90 (0∙16) 0∙02 (–0∙00 to 0∙03) ∙∙
GUI
Baseline 361 0∙89 (0∙11) 355 0∙89 (0∙12) ∙∙ ∙∙
6 months 330 0∙90 (0∙11) 329 0∙91 (0∙10) 0∙01 (–0∙00 to 0∙03) ∙∙
12 months 315 0∙89 (0∙12) 320 0∙91 (0∙11) 0∙01 (–0∙00 to 0∙03) ∙∙
18 months 305 0∙89 (0∙12) 303 0∙90 (0∙13) 0∙01 (–0∙01 to 0∙02) ∙∙
24 months 298 0∙89 (0∙12) 305 0∙90 (0∙11) 0∙02 (0∙00 to 0∙03) ∙∙
30 months 299 0∙88 (0∙12) 291 0∙89 (0∙12) 0∙02 (0∙00 to 0∙03) ∙∙
36 months 300 0∙89 (0∙13) 303 0∙89 (0∙13) 0∙01 (–0∙01 to 0∙02) ∙∙
GSS
Baseline 357 83∙3 (16∙6) 353 81∙4 (17∙2) ∙∙ ∙∙
6 months 321 83∙0 (16∙3) 320 85∙6 (14∙9) 4∙0 (2∙0 to 6.0) ∙∙
12 months 310 83∙0 (17∙6) 309 85∙2 (15∙4) 2∙9 (0∙8 to 4∙9) ∙∙
18 months 295 83∙1 (16∙8) 294 84∙6 (15∙8) 2∙8 (0∙7 to 4∙8) ∙∙
24 months 287 83∙3 (16∙4) 290 83∙3 (16∙3) 1∙4 (–0∙7 to 3∙5) ∙∙
30 months 288 81∙3 (17∙6) 276 84∙1 (16∙7) 3∙5 (1∙5 to 5∙6) ∙∙
36 months 282 83∙3 (17∙3) 296 83∙1 (17∙7) 2∙2 (0∙1 to 4∙2) ∙∙
GQL-15
Baseline 361 18∙7 (5∙6) 355 18∙9 (6∙6) ∙∙ ∙∙
6 months 323 18∙8 (5∙6) 324 18∙3 (5∙4) –0∙8 (–1∙6 to 0∙0) ∙∙
12 months 314 19∙2 (7∙2) 318 18∙8 (6∙6) –0∙5 (–1∙4 to 0∙3) ∙∙
18 months 302 19∙1 (6∙4) 298 18∙9 (6∙5) –0∙6 (–1∙4 to 0∙2) ∙∙
24 months 289 19∙5 (7∙3) 298 19∙2 (6∙7) –0∙5 (–1∙3 to 0∙4) ∙∙
30 months 293 19∙9 (7∙1) 287 19∙6 (7∙9) –0∙3 (–1∙1 to 0∙5) ∙∙
36 months 298 19∙8 (7∙8) 304 19∙8 (7∙2) –0∙4 (–1∙2 to 0∙4) ∙∙
SLT=selective laser trabeculoplasty. EQ-5D=EuroQol EQ-5D (higher scores represent a better quality of life). 
GUI=Glaucoma Utility Index (higher scores represent a higher quality of life). GSS=Glaucoma Symptom Scale (higher 
scores represent better outcomes). GQL-15=Glaucoma Quality of Life-15 (higher scores represent poorer glaucoma 
quality of life). QALY=quality-adjusted life-years. *(SLT eye drops); adjusted for baseline score, severity, centre, 
baseline intraocular pressure, and number of eyes affected at baseline. 
Table 4: Primary and secondary analysis of health-related quality-of-life questionnaires
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GQL­15) generally suggested better health­related 
quality­of­life outcomes for the selective laser trabeculo­
plasty group (figure 2).
At 36 months, 536 (87·7%) of 611 eyes in 314 patients in 
the selective laser trabeculoplasty group and 536 eyes 
(86·2%) of 622 eyes in 312 patients in the eye drops 
group were available for analysis of clinical outcomes 
(table 5). The groups had similar endpoint visual acuity, 
intraocular pressure, and visual field loss mean deviation 
(table 5).
Overall 509 (95%) of 536 eyes treated with selective 
laser trabeculoplasty were at target intraocular pressure 
at 36 months. Target intraocular pressure was achieved 
without intraocular pressure medication in 419 (78·2%) 
of 536 eyes treated in the selective laser trabeculoplasty 
group (table 5); of these 321 (76·6%) required only 
one treatment. 233 of the patients in the selective laser 
trabeculoplasty group (74·2%, 95% CI 69∙3%–78∙6%) 
were drop­free at 36 months. 499 (93·1%) of the 526 eyes 
treated in the eye drops group were at target intraocular 
pressure at 36 months, and 346 (64·6%) were using a 
single medication. Over 36 months, for 93·0% visits 
(according to decision support software) patients in the 
selective laser trabeculoplasty group were at target 
intraocular pressure compared with 91·3% in the eye 
drops group (table 5).
More treatment escalations took place in the selective 
laser trabeculoplasty group (n=348) than in the eye drops 
group (n=299). 36 eyes in the eye drops group showed 
algorithm­confirmed disease deterioration (three eyes 
converted from ocular hypertension to OAG and in 
33 eyes OAG progressed) compared with 23 eyes in the 
selective laser trabeculoplasty group (two eyes converted 
from ocular hypertension to OAG and in 21 eyes OAG 
worsened). 25 cataract extractions were carried out in the 
eye drops group compared with 13 in the selective laser 
trabeculoplasty group. 11 eyes (1·8%) required surgery to 
lower intraocular pressure (trabeculectomy) in the eye 
drops group (five eyes had uncontrollable intraocular 
pres sure, four eyes had uncontrollable intraocular pres­
sure and visual field loss progression, one eye had visual 
field loss progression, and one eye had uncontrollable 
intraocular pressure, visual field loss progression, and 
disc progression) compared with none in the selective 
laser trabeculoplasty group.
There were no sight­threatening complications of select­
ive laser trabeculoplasty (table 6). Cases of reactivation of 
herpes simplex keratitis (one in each treatment group) and 
uveitis (two in the selective laser trabeculoplasty group and 
one in the eye drops group) were similar. In six eyes of 
six patients, the intraocular pressure rose on the day of 
laser treatment by more than 5 mm Hg, but only one eye 
required treatment. There were more ophthalmic­drop­
related adverse events reported by patients in the eye drops 
group (150 aesthetic side effects or ocular allergic reactions 
reported by 73 patients) compared to the selective laser 
trabeculoplasty arm (30 events reported by 20 patients). 
122 (34∙4%) of 355 patients in the selective laser 
trabeculoplasty group reported transient discomfort, 
blurred vision, photophobia, and hyperaemia. Adverse 
events, including variations in number of laser shots able 
to be delivered, were reported for 14 patients during 
selective laser trabeculoplasty. Systemic adverse events 
were similar overall between the two treatment groups 
(table 6). Drop­related systemic adverse events were 
reported more often and by more patients in the eye drops 
group (148 events reported by 52 [14·4%] of 361 patients 
compared with 87 events reported by 23 (6·5%) of 
355 patients in the selective laser trabeculoplasty group). 
Pulmonary problems and cardiac events were few and 
balanced between the two groups. Serious adverse events 
were also similar between the two groups: 95 in 68 patients 
in the eye drops group and 107 in 64 patients in the 
selective laser trabeculoplasty group.
The cost of selective laser trabeculoplasty over the 
duration of the trial was an additional £205 (95% CI 
196 to 213) in the selective laser trabeculoplasty group. 
Over the 36 months of the trial, drops for OAG and ocular 
hypertension cost an additional £465 (95% CI 440 to 491) 
for patients assigned to the eye drops group. The average 
cost per patient for ocular surgery over 36 months was 
significantly less for the selective laser trabeculoplasty 
group compared with the eye drops group (unadjusted 
difference –£134, SE 43; 95% CI –218 to –50; p=0·002) and 
for all ophthalmology costs including selective laser 
trabeculoplasty and drops (unadjusted difference –£451, 
SE 66; 95% CI –580 to –322; p<0·001). Selective laser 
Figure 2: Mean EQ-5D, GUI, GSS, and GQL-15 scores at each time point, across 36 months
Time-point ‘0’ refers to pre-treatment. EQ-5D=EuroQol 5 Dimensions 5 Levels. GUI=Glaucoma Utility Index. 
GSS=Glaucoma Symptom Scale. GQL-15=Glaucoma Quality of Life-15. *Higher scores indicate better 
health-related quality of life. †Higher scores indicate worse health-related quality of life.
EQ-5D* GUI*
GSS* GQL-15†
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trabeculoplasty as first­line treatment resulted in more 
QALYs than eye drops first (table 4, but the difference was 
not significant p=0·286), for a lower cost and so no 
incremental cost­effectiveness ratio is reported. Imputing 
missing EQ­5D­5L utilities using multiple imputation and 
accounting for the correlation between costs and QALYs, 
using seemingly unrelated regression, selective laser 
trabeculoplasty as first­line treatment costs £458 less than 
eye drops first with 95% of bootstrap iterations falling 
between –£585 and –£345 (for specialist eye­related costs) 
and has a mean incremental QALY of 0·011, with 95% 
bootstrap iterations falling between –0·024 and 0·050. 
Over 36 months, discounted and adjusted, at a £20 000 and 
£30 000 willingness to pay for a QALY gained, there is a 
97% and 93% probability that selective laser trabeculoplasty 
first is more cost­effective than eye drops first when only 
ophthalmology costs are included, and a 68% chance for 
both £20 000 and £30 000 when community and non­eye 
related costs are added (appendix). A greater total number 
of clinic visits in the selective laser trabeculoplasty group 
than in the eye drops group (3441 vs 2907) was due to an 
additional protocol­mandated intraocular pressure check 
2 weeks after laser (465 visits), at which no complications 
affecting management were detected and which is no 
longer part of routine clinical practice.
Discussion
In this multicentre randomised controlled trial we com­
pared initial treatment of OAG or ocular hyper tension 
using selective laser trabeculoplasty followed by medi­
cation, if required, against the standard medication for 
lowering intraocular pressure alone. We demonstrated 
that the treatment pathway with initial selective laser 
trabeculoplasty is cost­effective with no significant differ­
ence in health­related quality of life and clinical out­
comes, and lower cost compared with the conventional 
treatment pathway, where medi cation is used from the 
outset.
Our treat­to­target design tailored treatment intensity 
to disease severity and the treatment response. In the eye 
drops group, 36 patients (5·8%) had disease pro gression 





Total number of SLT treatments at 
36 months
6* 770
Number of SLT treatments per eye
One 6 (1∙0%) 453 (74∙1%)
Two 0 (0%) 157 (25∙7%)
Three† 0 (0%) 1 (0∙2%)
Number of medications per eye at target IOP at 36 months‡
No medication 16 (3∙0%) 419 (78∙2%)
One 346 (64∙6%) 64 (12∙0%)
Two 99 (18∙5%) 21 (3∙9%)
Three 35 (6∙5%) 4 (0∙8%)
Four 3 (0∙6%) 1 (0∙2%)
Eyes not at target at 36 months 37 (7∙0%) 27 (5∙0%)
Control of disease
Visits at target (cumulative) 91∙3% 93∙0%
Eyes at target IOP at 36 months 499 (93∙1%) 509 (95∙0%)
OHT 127 (92∙0%) 151 (95∙6%)
Mild OAG 261 (94∙6%) 259 (96∙3%)
Moderate OAG 69 (94∙5%) 55 (96∙5%)
Severe OAG 42 (85∙7%) 44 (84∙6%)
Treatment escalations§ 348 299
Disease progression during the trial 36 (5∙8%) 23 (3∙8%)
From OHT to OAG¶ 3 2
OAG progression 33 21
Algorithm defined VF progression 27 18
Algorithm defined optic disc 
progression
3 2
Algorithm defined VF and disc 
progression
3 1
Ocular surgeries during the trial
Phacoemulsification 25 13
Trabeculectomy 11 0
Trabeculectomy revision 7 (5 eyes) 0




(Continued from previous column)
Clinical endpoints at 36 months
Visual acuity (LogMAR) 0∙08 (0∙17) 0∙07 (0∙18)
OHT 0∙08 (0∙19) 0∙02 (0∙15)
Mild OAG 0∙06 (0∙15) 0∙08 (0∙17)
Moderate OAG 0∙12 (0∙16) 0∙11 (0∙24)
Severe OAG 0∙16 (0∙23) 0∙15 (0∙18)
IOP (mm Hg) 16∙3 (3∙87) 16∙6 (3∙62)
OHT 18∙7 (3∙73) 18∙2 (3∙73)
Mild OAG 15∙7 (3∙45) 16∙4 (3∙17)
Moderate OAG 14∙7 (3∙49) 14∙4 (3∙07)
Severe OAG 15∙5 (4∙17) 15∙5 (4∙16)
VF MD (dB) –3∙21 (3∙76) –3∙19 (3∙92)
OHT –0∙94 (1∙92) –1∙05 (1∙98)
Mild OAG –2∙14 (1∙95) –1∙99 (1∙93)
Moderate OAG –7∙21 (1∙92) –7∙96 (2∙04)
Severe OAG –10∙50 (5∙01) –10∙24 (4∙93)
Clinic visits
Total number of clinic visits 2907 3441
Total number of clinic visits excluding 
2-week IOP check
2907 2976
Data are n (%) unless otherwise stated. SLT=selective laser trabeculoplasty. 
IOP=intraocular pressure. OHT=ocular hypertension. OAG=primary open angle 
glaucoma. VF=visual field. MD=mean deviation. *Three patients (six eyes) in the 
eye drops group wanted SLT at treatment escalation. †Protocol deviation. 
‡Includes eyes that had undergone trabeculectomy. §Escalations initiated by the 
algorithm and the clinicians. ¶Conversion of OHT to OAG required a sign of 
progression derived from decision support software and verification by a 
consultant ophthalmologist.
Table 5: Measurements of pathway effectiveness and visual function
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trabeculoplasty group, 74% of whom remained drop­free 
at 3 years. The laser first approach provided better control 
of intraocular pressure over the course of 36 months, 
with more visits at target intraocular pressure compared 
with eye drops, less intense drop treatment, and with no 
glaucoma surgeries. This difference may be because 
control of intraocular pressure after laser relies on patient 
adherence with treatment; indeed, one report28 found 
patients had drops to lower intraocular pressure available 
only 69% of the time, and concordance has been reported 
to range between 76% and 86%.28 Selective laser 
trabeculoplasty has also been proposed to provide better 
diurnal intra ocular pressure stability, from its continuous 
effect on the trabecular meshwork, in contrast to the 
necessarily episodic administration of medication.29 By 
36 months, patients in the selective laser trabeculoplasty 
group had lower rates of disease deterioration compared 
with those in the eye drops group) and that 11 eyes 
required surgery to lower intraocular pressure in the eye 
drops group, but none in the selective laser 
trabeculoplasty group.
Primary selective laser trabeculoplasty gave drop­free 
control intraocular pressure for at least 36 months to 
74·2% of patients (95% CI 69·3%–78·6%), substantially 
higher than in previous studies30–33 with less stringent 
success cri teria, where selective laser trabeculoplasty was 
used as both a primary and adjunctive treatment. Prior 
treatment and more severe disease has been suggested to 
reduce the degree to which selective laser trabeculoplasty 
lowers intraocular pressure,34 possibly explaining our 
positive results in treatment­naive patients. This is 
the first study that reports disease control without 
topical medication, provided by primary selective laser 
trabeculoplasty, and does so with realistic but stringent 
Eye drop group (n=362) SLT (n=356) Total (n=718)
Number of events Number of 
patients (%)
Number of events Number of 
patients (%)
Number of events Number of 
patients (%)
Adverse events 1196 260 (71∙8%) 906 261 (73∙3%) 2096 521 (72∙6%)
Ocular
Aesthetic side effects of 
medication*
117 56 (15∙5%) 12 7 (2∙0%) 129 63 (8∙8%)
Ophthalmic allergic reactions† 33 17 (4∙7%) 18 13 (3∙7%) 51 30 (4∙2%)
Reactivation of herpes simplex 
keratitis
1 1 (0∙3%) 1 1 (0∙3%) 2 2 (0∙3%)
Uveitis 1 1 (0∙3%) 2 2 (0∙6%) 3 3 (0∙4%)
Other‡ 744 221 459 186 1203 407
SLT-related ocular
Inflammation after SLT 0 0 (0%) 1 1 (0∙3%) 1 1 (0∙1%)
IOP spike after SLT§ 0 0 6 6 (1.7%) 6 6 (0∙8%)
Other transient events¶ 2 1 (0∙3%) 171 122 (34∙4%) 173 123 (17∙2%)
Patients with an adverse event 
during SLT procedure||
∙∙ 0 ∙∙ 14 (3∙9%) ∙∙ 14 (1∙9%)
Systemic**
Pulmonary problems†† 23 14 (3∙9%) 24 12 (3∙4%) 47 26 (3∙6%)
Cardiac events 6 5 (1∙4%) 8 5 (1∙4%) 14 10 (1∙4%)
Drug-related events‡‡ 148 52 (14∙4%) 87 23 (6∙5%) 235 75 (10∙5%)
Other§§ 121 82 (22∙7%) 117 78 (22%) 238 160 (22∙3%)
Serious adverse events 95 68 (18∙8%) 107 64 (18∙0%) 202 132 (18∙4%)
Ocular¶¶ 7 6 (1∙7%) 10 8 (2∙2%) 17 14 (1∙9%)
Pulmonary problems|||| 3 3 (0∙8%) 2 2 (0∙5%) 5 5 (0∙7%)
Cerebrovascular accidents 1 1 (0∙3%) 2 2 (0∙5%) 3 3 (0∙4%)
Cardiac events 7 7 (1∙9%) 9 8 (2∙2%) 16 15 (2∙1%)
Cancer 9 8 (2∙2%) 15 13 (3∙6%) 24 21 (2∙9%)
Death 2 2 (0∙5%) 8 8 (2∙2%) 10 10 (1∙4%)
Other systemic 66 50 (15∙3%) 61 43 (12∙1%) 127 93 (13%)
SLT=selective laser trabeculoplasty. IOP=intraocular pressure. *Includes excessive lash growth, peri-ocular pigmentation, change in iris colour. †Includes peri-ocular skin rash. 
‡Includes ocular irritation, discomfort, dry eye, retinal haemorrhages, vision changes, flashes, floaters, conjunctivitis, blepharitis, vascular occlusions, diabetic retinopathy, 
macular pathology. §IOP spike defined as >5 mm Hg; only one eye received treatment. ¶Includes discomfort, transient blurred vision, transient photophobia, hyperaemia. 
||Includes discomfort, variation in the number of laser shots, angle visualisation issues. **Not requiring hospital admission. ††Asthma, shortness of breath, reduced exercise 
tolerance. ‡‡includes impotence, depression, somnolence or tiredness, nightmares, taste disturbance, generalised skin rash. §§Unrelated events, such as headaches, pain, 
falls. ¶¶Includes central retinal artery occlusion, choroidal neovascularisation, epiretinal membrane, angle closure, anterior chamber surgery, corneal pathologies, trauma, 
and any treatment required for these pathologies. ||||Requiring hospital admission.
Table 6: Adverse events
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targets for intraocular pressure and objective escalation 
criteria. Pre­trial patient and public involvement activities 
with glaucoma patients identified drop­free disease control 
as the most desired outcome. 90% of patients in a focus 
group felt being drop­free even in one eye only would be of 
benefit. Concerns about drop use, particularly associated 
with challenges from cognitive impairment and failing 
grip strength, were rated a priority by patients in the James 
Lind Alliance survey of sight loss research questions.35
We also demonstrate a greater safety of selective laser 
trabeculoplasty than previously reported, with low rates of 
selective laser trabeculoplasty­related adverse events. 
There were no systemic adverse events as a result of 
selective laser trabeculoplasty; only one patient in which 
selective laser trabeculoplasty caused a spike in intra­
ocular pressure required treatment, out of 776 selective 
laser trabeculoplasties, compared to reported rates up to 
28·8%.31 This is possibly due to treat ment at an earlier 
stage of disease. The intraocular pressure check 
conventionally done 2 weeks after selec tive laser 
trabeculoplasty did not change manage ment for any of 
the patients and consequently appears un necessary. 
Abandonment of this routine check could further increase 
the cost­effectiveness of selective laser trabeculoplasty. 
There was a lower rate of cataract surgery in the selective 
laser trabeculoplasty group, supporting existing evidence 
that eye drops to lower intraocular pressure are associated 
with a greater incidence of nuclear cataract and earlier 
need for surgical removal.18
Use of selective laser trabeculoplasty as the first­line 
treatment resulted in a significant reduction in the cost of 
surgery and medication for ocular hypertension and OAG, 
with an overall cost saving to the NHS of £451 per patient 
in specialist ophthalmology costs; for every patient given 
selective laser trabeculoplasty first instead of eye drops the 
cost savings are greater than the cost of selective laser 
trabeculoplasty for two additional patients, or equal to the 
cost of five additional ophthalmology specialist appoint­
ments. At a £20 000 willingness to pay for a QALY gained 
there is a 97% probability that selective laser trabeculo­
plasty is a cost­effective treatment for OAG and ocular 
hyper tension. Resource use for these costs was collected 
from patient files and trial monitoring data and hence is 
likely to be complete, with limited bias as a result of loss to 
follow­up or missing data. Including non­eye related 
health­care costs, the average cost per patient for selective 
laser trabeculoplasty as first treatment remained less than 
that for eye drops as first treatment, but the differences 
between the two groups were not significant, with the 
wide con fidence intervals resulting in a 68% probability 
that selective laser trabeculoplasty first is cost­effective 
com pared with eye drops. Non­ocular health­care cost data 
are, however, based on self­reported health­care resource 
use and may be unreliable or incomplete. Expensive 
systemic adverse events unrelated to ocular hypertension 
or OAG, such as cancer or cardiac events, may have also 
skewed the cost results. Previous economic assessments 
have attempted to estimate the relative costs of selective 
laser trabeculoplasty using economic modelling or esti­
mates of the treatment costs, instead of a direct cost 
assessment.36 Compared to monotherapy or multiple drug 
therapy and allowing for repetition of selective laser 
trabeculoplasty within 2–3 years, cost­savings have been 
predicted at 6 years for a Canadian health­care system.12 
The present study was done in an NHS setting, following 
pragmatic clinical approaches for the treatment of OAG 
and ocular hypertension and indicates that selective laser 
trabeculoplasty is cost effective over a 3­year period.
These findings have important implications for patients 
and health­care systems. Patients are concerned about the 
use of drops to lower intraocular pressure and widespread 
uptake of selective laser trabeculoplasty as first line 
treatment would lead to a drop­free interval of at least 36 
months for almost three quarters of patients, while 
providing savings for the NHS. Where necessary 
additional selective laser trabeculoplasty (documented to 
be effective) could increase the duration of this drop­free 
window. Patients with OAG have an average 9–13 years 
life expectancy from diagnosis,37 and so a 3 year or longer 
drop­free period might confer significant benefits to their 
remaining quality of life. The requirement for intense 
medical or surgical regimes might be deferred or 
completely averted by selective laser trabeculoplasty with 
potentially improved surgical success rates and still lower 
cost.8
This study mirrored pragmatic clinical practice by 
tailoring treatment to the patient. Individual intraocular 
pressure targets were based on pre­treatment intraocular 
pressure and disease severity, and adapted both to treat­
ment response and disease progression. Con sequently, 
our findings on disease progression, achieve ment of target 
intraocular pressure, and cost are highly relevant to normal 
clinical practice. The unique treat­to­target design with 
computerised decision­supported treatment interventions 
and follow­up intervals captured the com plexity of real­life 
clinical decision making and yet allowed impartial, objec­
tive, and unbiased decisions based on clinical obser vations. 
An unmasked design was essential to capture any potential 
effects (adverse or positive) from the patients’ perception 
of their treat ments, as may occur in clinical reality. 
This is because an important benefit of selective laser 
trabeculoplasty is a drop­free treatment window; a study 
design requiring a treat ment arm with placebo drops 
would have pre vented assessment of benefits attributable 
to drop free dom. We also sought to capture the impact of 
treatment on subsequent medication­taking behaviours 
and con cord ance. Similarly, treating clinicians had to be 
un masked to be able to choose appropriate treatment 
escalations. Our results are widely generalisable, as 
we included patients with ocular hypertension and both 
low­pressure and high­pressure OAG, from a range 
of backgrounds and ethnic origins. There are also impor­
tant implications for resource­poor health­care settings, 
where access to medi cation is a major barrier to glaucoma 
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treatment. Adequate drop­free control of intraocular 
pressure for years is a promising treatment approach for 
regions of Africa where glaucoma preva lence is high. 
Longer follow­up, already underway, will permit us to 
answer further questions regarding the effect of prior 
selective laser trabeculoplasty on later medication­taking 
behaviour, treat ment intensity, and longitudinal health­
related quality of life.
Our primary outcome of health­related quality of life, 
assessed using the EQ­5D questionnaire, a generic tool 
eliciting utility values in multiple settings, was required by 
our funder as a requirement of NICE cost­utility analyses. 
Recently, the sensitivity of EQ­5D in ophthalmology has 
been questioned and particularly so for glaucoma, which 
can be asymptomatic, even at levels sufficient to make 
driving unsafe.38 While potentially blinding over longer 
periods, only small changes in vision occur in the duration 
of a clinical trial. The above average health­related quality 
of life at baseline, the weak sensitivity of the EQ­5D to 
detect glaucoma­specific effects on health­related quality 
of life,39 and relatively short duration of LiGHT compared 
to the time for disease progression may have contributed 
to the lack of superiority of selective laser trabeculoplasty 
with respect to EQ­5D.
Since glaucoma­specific instru ments better capture 
differences in glaucoma severity than does the effect of 
treatment side effects on health­related quality of life, the 
lack of a significant difference in the GUI and GQL­15 
might also be expected. Differ ences in health­related 
quality of life would arise from differ ences in drop usage, 
due to inconvenience or side­effects. The GSS evaluates a 
visual and an ocular com fort related domain, and 
incorporates treatment side­effect­related measures. 
Better GSS scores for the select ive laser trabeculoplasty 
group could represent differ ences that arise from drop 
usage, but potentially reflect differ ences in baseline 
scores between the different treat ment groups.
Our data support a change in practice; however, 
clinicians will need to consider patients’ perceptions of 
the necessity of monitoring visits, in the absence of daily 
medication. Primary selective laser trabeculoplasty is a 
cost­effective alternative to drops that can be offered to 
patients with OAG or ocular hypertension needing 
treatment to lower intraocular pressure.
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